Abstract
Get full access to this article
View all access options for this article.
References
1.
Todd
PA
Brogden
RN
. Muromonab CD3. A review of its pharmacology and therapeutic potential . Drugs
1989 ; 37 : 871 –99 .
2.Ortho Multicenter Transplant Study Group . A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants . N Engl J Med
1985 ; 313 : 337 –42 .
3.
Thistlethwaite
JR
Gaber
AO
Haag
BW
, OKT3 treatment of steroid-resistant renal allograft rejection . Transplantation
1987 ; 43 : 176 –84 .
4.
Emmons
C
Smith
J
Flanigan
M
. Cerebrospinal inflammation during OKT3 therapy . Lancet
1986 ; 2 : 510 –1 .
5.
Martin
MA
Masarani
M
Nghiem
DD
Smith
JL
Corry
RS
. Nosocomial aseptic meningitis associated with administration of OKT3 . JAMA
1988 ; 13 : 2002 –4 .
6.
Miller
RA
Maloney
DG
McKillop
J
Levy
R
. In vivo effects of murine hybridoma monoclonal antibody in a patient with T-cell leukemia . Blood
1981 ; 58 : 78 –86 .
7.
Williams
AF
Gagnon
J
. Neuronal cell Thy-1 glycoprotein: Homology with immunoglobulin . Science
1982 ; 216 : 696 –703 .